Yondelis

by Johnson & Johnson

Yondelis is an IV chemotherapy for soft tissue sarcoma and ovarian cancer available through the Johnson & Johnson Patient Assistance Program.

Yondelis (trabectedin) is a marine-derived antineoplastic agent originally isolated from the sea squirt Ecteinascidia turbinata. It is approved for the treatment of unresectable or metastatic liposarcoma or leiomyosarcoma in adults who received a prior anthracycline-containing regimen, and in combination with pegylated liposomal doxorubicin (PLD) for relapsed platinum-sensitive ovarian cancer. Yondelis binds to the minor groove of DNA, disrupting transcription and DNA repair mechanisms in cancer cells. It is administered as an intravenous infusion in a clinical setting over 24 hours every three weeks.

Patient assistance programs

Johnson & Johnson Patient Assistance Program (J&J withMe)

Manufacturer PAP
Eligibility
Uninsured or underinsured adults with a valid Yondelis prescription from a licensed U.S. oncologist who meet income requirements.
Income limit
Varies based on household size; generally ≤400% of Federal Poverty Level (FPL)
Insurance
Uninsured or underinsured
How to apply
Apply through ClariMeds — we handle all paperwork at no cost to you. Applications are submitted directly to J&J withMe on your behalf.

Need help applying?

ClariMeds handles the entire application process for you — for free. See if you qualify in minutes.

See If You Qualify — Free